07:05 AM EDT, 10/02/2024 (MT Newswires) -- Genenta Science (GNTA) said Wednesday it received approval from the Italian Medicines Agency for a phase 1 clinical trial evaluating the company's drug Temferon in treating metastatic renal cell cancer.

The trial is expected to commence in Q4, Genenta said. It will target patients with a median overall survival that is currently less than 2 years after multiple lines of therapy, the company added.